This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CRAIG M. PALMER, MD
Department of Anesthesiology University of Arizona Health Sciences Center 1501 N Campbell Tucson, AZ 85724

MARK C. NORRIS, MD
Department of Anesthesiology Thomas Jefferson University Hospital 1025 Walnut St Philadelphia, PA 19107

Am J Dis Child. 1990;144(2):144.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—Flecainide, a local anesthetic–type antiarrhythmic agent, has recently been approved for use in the United States. To augment the little available information regarding its use during pregnancy and effects on the neonate, we present the following patient report.

Patient Report.—A 24-year-old woman, gravida 5, para 1-0-3-1, presented at 37 weeks' gestation with spontaneous rupture of membranes. Review of her medical history revealed mitral valve prolapse with moderate to severe mitral regurgitation. In the fifth month of her pregnancy she began taking metoprolol for increasingly symptomatic supraventricular tachycardia, with an initial good response. By 35 weeks' gestation, however, the patient's symptoms had worsened; a repeated electrocardiogram at that time disclosed Wolf-Parkinson-White syndrome, type A. Administration of metoprolol was discontinued, and she began taking flecainide, 100 mg by mouth two times per day; the dosage was subsequently increased to 150 mg two times per day, with symptomatic improvement.

Continuous . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?